NCT05743075View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

526

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

December 6, 2024

Study Completion Date

March 7, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Ensifentrine

A dual PDE3/PDE 4 inhibitor

DRUG

Placebo

Placebo solution

Trial Locations (1)

Unknown

1st Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Laboratory Corporation of America

INDUSTRY

lead

Nuance Pharma (shanghai) Co., Ltd

INDUSTRY